Over 90 Total Lots Up For Auction at One Location - WA 04/08

First patients treated with proton therapy in Belgium with IBA's ProteusONE

Press releases may be edited for formatting or style | September 16, 2020 Rad Oncology Proton Therapy

* Proteus®ONE is the brand name of Proteus®235.
** ARC therapy is work in progress and FLASH therapy is currently under research. They are not available for sale.


About ParTICLe Proton Therapy Center
ParTICLe is a consortium of UZ Leuven / KU Leuven and Cliniques Universitaires Saint-Luc / UCL, together with UZ Gent, UZA, UZ Brussel and CHU UCL Namur, which will develop one joint interuniversity treatment and research center for proton therapy in Belgium, within a context of thorough medical and strategic cooperation with all interested centers and partners. Patients are now able to receive proton therapy treatment in the ParTICLe proton therapy center in Leuven. It is estimated that in Belgium, according to current standard indications, 150 to 200 patients are eligible for proton therapy every year. These will mainly be children with cancer and adults with certain rare cancers for which existing solutions are not optimal, such as tumors at the base of the skull, close to the spine or near the optic nerve. This number may increase in the future if new indications for proton therapy are determined on the basis of clinical scientific studies.

Back to HCB News

You Must Be Logged In To Post A Comment